Neurogenesis
Neurodegenerative Disease Cell Therapy
Company Overview
Snapshot
Founded in September 2018 by Tal Gilat, Ibrahim Kassis, and Dimitrios Karussis, Neurogenesis operates with 1–10 employees. The company has raised $7.66M across two funding rounds from three investors. In May 2026, Neurogenesis secured a grant from the BIRD Foundation.
Business overview
Neurogenesis is a clinical-stage cellular therapy company focused on developing treatments for central nervous system diseases. The company utilizes a proprietary subpopulation of bone marrow stem cells, which are selected and enhanced to act as remyelinating and regenerative biofactory cells. Its NG CELL technology platform is specifically designed to address conditions such as progressive multiple sclerosis and amyotrophic lateral sclerosis, operating within the Health Tech & Life Sciences sector.
Strategic signal
In May 2026, Neurogenesis received a grant from the BIRD Foundation as part of new U.S.-Israel projects. This funding validates the company's innovative approach to cell therapy for neurodegenerative diseases and signals continued support for its research and development efforts, potentially accelerating its clinical programs.
Company Intelligence Q&A
- What is Neurogenesis's core technology?
- Neurogenesis's core technology is the NG CELL platform, which utilizes a proprietary subpopulation of bone marrow stem cells selected and enhanced to become remyelinating and regenerative biofactory cells for treating central nervous system diseases.
- What significant funding did Neurogenesis receive in 2026?
- In May 2026, Neurogenesis secured a grant from the BIRD Foundation as part of new U.S.-Israel projects.
- Which investors participated in Neurogenesis's March 2022 funding round?
- In March 2022, Neurogenesis received funding from investors including Rhodium and Excell Partners.
- What diseases does Neurogenesis's technology aim to treat?
- Neurogenesis's NG CELL technology is designed to treat central nervous system diseases, specifically progressive multiple sclerosis and amyotrophic lateral sclerosis.